Tonix Pharmaceuticals Holding Investor Presentation — December 2019

Document content

© 2019 Tonix Pharmaceuticals Holding Corp.1

Version P0208 12-3 -19 (Doc 0565)

Investor Presentation

© 2019 Tonix Pharmaceuticals Holding Corp.2

Cautionary Note on Forward

Certain statements inthispresentation regarding strategic plans, expectations andobjectives forfuture

operations orresults are“forward -looking statements” asdefined bythePrivate Securities Litigation Reform

Actof1995.These statements may beidentified bytheuseofforward -looking words such as“anticipate,”

“believe,” “forecast,” “estimate” and“intend,” among others .These forward -looking statements arebased on

Tonix’s current expectations andactual results could differ materially .There areanumber offactors that

could cause actual events todiffer materially from those indicated bysuch forward -looking statements. These

factors include, butarenotlimited to,substantial competition ;ourneed foradditional financing ;uncertainties

ofpatent protection andlitigation ;uncertainties ofgovernment orthird party payor reimbursement ;limited

research anddevelopment efforts anddependence upon third parties ;andrisks related tofailure toobtain

U.S.Food andDrug Administration clearances orapprovals andnoncompliance withitsregulations .Aswith

anypharmaceutical under development, there aresignificant risks inthedevelopment, regulatory approval

andcommercialization ofnewproducts .Theforward -looking statements inthispresentation aremade asof

thedateofthispresentation, even ifsubsequently made available byTonix onitswebsite orotherwise .Tonix

does notundertake anobligation toupdate orrevise anyforward -looking statement, except asrequired by

law.Investors should read theriskfactors setforth intheAnnual Report onForm 10-Kfortheyear ended

December 31,2018, asfiledwiththeSecurities andExchange Commission (the“SEC”) onMarch 18,2019,

andperiodic reports andcurrent reports filedwiththeSEConorafter thedatethereof .AllofTonix's forward -

looking statements areexpressly qualified byallsuch riskfactors andother cautionary statements .© 2019 Tonix Pharmaceuticals Holding Corp.3

•A clinical stage biopharmaceutical company dedicated to developing innovative treatments

for patients and making meaningful contributions to society

•Focusing on small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter -measures and to

prevent and treat organ transplant rejection

•Target therapeutic areas with high need for improvement

−Conditions with no, or inadequate, treatments